Will Report Record Revenue in Both Collaborations and Product Sales for 2016; Near-Term Debt Maturities Have Been Resolved; Completed Strategic Transition Out of Commodity Products

 

EMERYVILLE, Calif., Feb. 03, 2017 -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today provided an update on certain aspects of its business and financial results for 2016.

 

“We are pleased to have achieved a record year of revenue growth, and of having completed all of the 2016 strategic milestones we set out to, and we continue to make good progress on our debt structure by having resolved our near-term debt maturity issues in pushing out approximately $44 million in debt as announced just before year end,” said John Melo, Amyris President & CEO. “Also, we are meeting our expectations in securing collaborations that will result in future product sales and this is accelerating our growth rate.”

Will Also Report Second Quarter 2017 Results and Discuss Next Steps in its Development Programs

Teleconference and Webcast to be held on February 9, 2017

 

CRANBURY, N.J., Feb. 3, 2017  -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced the closing of its license agreement with AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) for exclusive North American rights to develop and commercialize Rekynda™ (bremelanotide), an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women.  Palatin received an initial payment of $60,000,000 under the license agreement.

- Data to be presented at industry leading conferences

- Development of novel viral vectors for delivery to the back of the eye

- Expanded potential of developing ddRNAi technology into ocular indications

 

SYDNEY, Feb. 2, 2017 -- Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce today that it has made significant progress with the Company's ddRNAi technology for the development of therapeutics for the treatment of ocular diseases.  Of particular importance is the output from Benitec's collaboration with 4D Molecular Therapeutics to identify novel viral vectors for delivery to the back of the eye using direct intravitreal injection, a commercially attractive route of administration. 

– Study Did Not Achieve Statistically Significant Reductions in Dual or Quad Primary Endpoints –

– Study Met Two Secondary Endpoints with Statistically Significant Reduction in Incidence of LCOS and Use of Postoperative Secondary Inotropes –

 

MORRISVILLE, N.C. -- Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced top-line results from its Phase 3 LEVO-CTS trial. The study did not achieve statistically significant reductions in the dual endpoint of death or use of a mechanical assist device at 30 days, nor in the quad endpoint of death, myocardial infarction, need for dialysis, or use of a mechanical assist device at 30 days. However, the study demonstrated statistically significant reductions in two of three secondary endpoints including reduction in low cardiac output syndrome (LCOS) and a reduction in postoperative use of secondary inotropes.